General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1H15 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects Lysophosphatidylcholine acyltransferase 1 (LPCAT1). It targets an epitope within 25 amino acids from the C-terminal half.
Immunogen
KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal half of human Lysophosphatidylcholine acyltransferase 1 (LPCAT1).
Application
Quality Control Testing
Evaluated by Western Blotting in A431 cell lysate.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected LPCAT1 in A431 cell lysate.
Tested applications
Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected LPCAT1 in PC3 and 1:1,000 dilution in RAW264.7 cell lysates.
Affinity Binding Assay: A representative lot of this antibody bound in LPCAT1 with a KD of 4.4 x 10-9 in an affinity binding assay.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected LPCAT1 in human cerebral cortex and human kidney tissue sections.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected LPCAT1 in A549 cells.
Flow Cytometry Analysis: 1 μg from a representative lot detected LPCAT1 in one million A431 cells.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-LPCAT1, clone 1H15 ZooMAb®, Cat. No. ZRB1279, is a recombinant Rabbit monoclonal antibody that specifically targets LPCAT1 and is tested in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, and Western Blotting.
Target description
Lysophosphatidylcholine acyltransferase 1 (UniProt: Q8NF37; also known as EC:2.3.1.23, LPC acyltransferase 1, LPCAT-1, LysoPC acyltransferase 1, 1-acylglycerol-3-phosphate O-acyltransferase, 1-acylglycerophosphocholine O-acyltransferase, 1-alkylglycerophosphocholine O-acetyltransferase, Acetyl-CoA:lyso-PAF acetyltransferase, Lyso-PAF acetyltransferase, LysoPAFAT Acyltransferase-like 2, Phosphonoformate immuno-associated protein 3) is encoded by the LPCAT1 (also known as AYTL2, PFAAP3) gene (Gene ID: 79888) in human. LPCAT-1 is a single-pass type II membrane protein with a cytoplasmic domain (aa 1-57), a transmembrane domain (aa 58-78), and a long lumenal domain (aa 78-534). It contains a HXXXXD motif in its N-terminal region (aa 135-140) that is shown to be essential for its acyltransferase activity and may constitute the binding site for the phosphate moiety of the glycerol-3-phosphocholine. In addition, it has a di-lysine motif (aa 531-534) that confers endoplasmic reticulum localization. LPCAT-1 catalyzes the conversion of lysophosphatidylcholine (1-acyl-sn-glycero-3-phosphocholine or LPC) into phosphatidylcholine and also catalyzes the conversion 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. It displays a clear preference for saturated fatty acyl-CoAs, and 1-myristoyl or 1-palmitoyl LPC as acyl donors and acceptors, respectively. LPCAT-1 is involved in platelet-activating factor (PAF) biosynthesis by catalyzing the conversion of the PAF precursor, 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) into PAF. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Soupene, E., et al. (2008). Proc. Natl. Acad. Sci. USA. 105(1); 88-93).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb® formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
Reconstitution
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.